smarcd2 regulates granulopoiesis in zebrafish As a first model organism, we used zebrafish (Danio rerio), in which smarcd2 (XP_692749.2) is the ortholog of human SMARCD2. Using antisense morpholino oligonucleotides (MOs), we created Smarcd2-deficient zebrafish in two reporter strains with fluorescent neutrophil granulocytes: Tg(mpx:EGFP) i114 ( Supplementary Fig. 4a-c and Supplementary Data 3a,b) and Tg(lyz:dsRed) nz50 (Fig. 4a) [17] [18] [19] . smarcd2 MOs were designed to block either translation initiation (label ATG) or splicing (labels SB1 and SB2, for MOs targeting splice donor and acceptor sites, respectively) of smarcd2. In both fish lines, there was a significant reduction in the number of neutrophil granulocytes in comparison to controls at 72 h post fertilization (h.p.f.) for the ATG and SB1 MOs ( Fig. 4a and Supplementary Fig. 4c ). MO SB2, which failed to disrupt smarcd2 splicing (Supplementary Fig. 4a ), provided an additional negative control indicating specificity of the on-target smarcd2 MO effect to reduce neutrophil abundance. Using CRISPR/Cas9 genome editing in zebrafish, we also created a frameshift mutant smarcd2 allele smarcd2 1/1 ( Supplementary Fig. 4d ), which also showed reduced granulocyte abundance at 72 h.p.f. in comparison to wild-type controls (Fig. 4b,c ). There were no marked effects of smarcd2 MO on zebrafish granulocyte morphology (Supplementary Fig. 5 ). There were no qualitative differences in O-dianisidine-stained hemoglobinized erythrocytes and no quantitative differences in numbers of Tg(mpeg1:mCherry) gl25xc264 -marked macrophages and Tg(cd41:EGFP) la2 -marked thrombocytes after smarcd2 MO knockdown (Supplementary Fig. 6 ). This underlines the lineage-specific effects of smarcd2. Collectively, these zebrafish models provide concordant evidence that a requirement for SMARCD2 in neutrophil granulocyte differentiation is evolutionarily conserved.
Knockout of Smarcd2 in mouse embryos
A second in vivo model was generated by injection of Smarcd2 +/− mouse ES cells (KOMP repository) into blastocysts and transfer of these cells into pseudo-pregnant mice. Chimeric offspring were mated with wild-type mice, resulting in Smarcd2 +/− mice, which were intercrossed ( Supplementary Fig. 7a,b) . We found that Smarcd2 −/− embryos died late during fetal development ( Supplementary Fig. 7c- 
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and Supplementary Data 3c-e) and were characterized by reduced size, pallor, and decreased temporal vascularization (Fig. 5a ), suggestive of a compromised hematopoietic system. However, we did find Mendelian ratios of Smarcd2 −/− embryos at 14.5 d post-coitum (d.p.c.) (Supplementary Fig. 7d ). Smarcd2 −/− embryos expressed SWI/SNF core members and the SMARCD1 and SMARCD3 paralog proteins ( Supplementary Fig. 7f and Supplementary Data 4). Flow cytometry analysis of fetal liver single-cell suspensions showed comparable numbers of HSCs ( Supplementary Fig. 7g ), yet a striking reduction in granulocyte-macrophage progenitors (GMPs) and of CD11b + Gr1 + neutrophil granulocytes and CD11b + Ly6c + monocytes in Smarcd2 −/− embryos versus Smarcd2 +/+ embryos (Fig. 5b,c) .
To assess the differentiation capacity of HSCs, we next purified CD45.2 + Lin -Mac +/lo Sca1 + c-Kit + (LSK) cells from wild-type, heterozygous, and homozygous fetal livers and performed colony-forming unit (CFU) assays in vitro. In comparison to CFU colonies derived from wild-type or heterozygous fetal liver LSK cells, knockout CFU colonies showed a marked reduction in size and numbers (data not shown and Supplementary Fig. 8a ) and maturation arrest (Fig. 5d) . Smarcd2 −/− myeloid CFU colonies, generated in the presence of myeloid cytokine cocktail, were deficient in cell surface expression of CD11b, Gr1, and Ly6c ( Supplementary Fig. 8b) . A block in myeloid differentiation was also seen when LSK cells (native) were exposed to any of GM-CSF, M-CSF, or G-CSF, suggesting that none of the corresponding cytokine receptors were able to induce myeloid cell growth (Fig. 5e) .
Aberrant hematopoiesis was not restricted to the myeloid compartment in Smarcd2 −/− embryos but also affected erythroid differentiation. Fetal/umbilical cord blood cytology at 14.5 d.p.c. showed marked dysplastic changes in Smarcd2 −/− erythropoiesis: In contrast to wild-type embryos, characterized by normochromic, orthochromatic erythrocytes and the presence of few nucleated erythrocytes, Smarcd2 −/− embryos showed extensive anisocytosis of erythrocytes, multinucleated cells, perturbed mitosis, and increased apoptosis (Fig. 5f) . Furthermore, in vitro erythroid differentiation of LSK cells in the presence of recombinant mouse SCF, recombinant mouse IL-3, recombinant human IL-6, and recombinant human EPO hints at a partial differentiation block or delay at the immature S1 stage, as determined by CD71/Ter119 expression 20 in Smarcd2 −/− GEMM colonies (Fig. 5g,h ). Taken together, mouse SMARCD2-deficient hematopoietic cell differentiation is characterized by a maturation arrest in myeloid and erythroid cells in vitro and in vivo, reminiscent of the hematological phenotype in SMARCD2 −/− patients.
Various previous studies found that SWI/SNF complex members increase or decrease primitive or definite hematopoiesis 6 . Hence, we hypothesize that (i) the functional effects of SMARCD2 deficiency on granulopoiesis are due to its absence from SWI/SNF complexes, 
(ii) SWI/SNF complexes that contain SMARCD2 have a specific role in granulopoiesis, and (iii) mechanistically, SMARCD2 governs granulopoiesis via chromatin accessibility and interaction with CEBPε.
SMARCD2 takes stage-specific roles in granulopoiesis
We continued our studies in mouse cells, taking a systems biology approach. To identify alterations in transcriptional networks controlling differentiation of fetal liver HSCs, we isolated LSK and myeloid progenitor cells (Fig. 6a) . We profiled the transcriptome by RNA-seq of LSK cells from five Smarcd2 +/+ and nine Smarcd2 −/− fetal livers. Among a total of 12,362 detected genes, we found 4,290 to be differentially expressed at a false discovery rate (Online Methods) lower than 10%. As expected, Smarcd2 showed the largest fold change in expression of all genes ( Fig. 6b and Supplementary Table 4) . Interestingly, the majority (79%) of the 605 genes with a relatively large difference (fold change > 1.4, FDR < 1%) were upregulated and not downregulated. This had also been reported for embryonic fibroblasts deficient for SMARCB1 (Snf5) and SMARCA4 (Brg1), two other members of the SWI/SNF complex 11 . The upregulated genes were most enriched in categories related to membrane proteins, including major histocompatibility complex (MHC) proteins, immunoglobulin domains, and G-protein-coupled receptors that included signaling pathways related to immunodeficiency and host defense ( Supplementary Fig. 9a and Supplementary  Tables 5 and 6a) . A subset of CEBPε-dependent genes (Supplementary Table 6b ) was also deregulated in Smarcd2 −/− mouse LSK cells (Supplementary Fig. 9b,c and Supplementary Table 6c) . Consistent with the finding that CpG island (CGI) promoters can facilitate promiscuous induction without a requirement for SWI/SNF 21 , we found that genes containing CGI promoters were significantly under-represented within the group of differentially expressed genes (Fisher's exact test, P = 0.004; odds ratio = 0.71). Thus, a considerable fraction of the genes that were found to be differentially expressed are directly dependent on SWI/SNF and/or transcription factors. (Fig. 6a and Supplementary Fig. 10a-c) . In contrast to the LSK, CMP, or MEP compartments, GMP cells were almost absent in Smarcd2 −/− fetal livers (compare Supplementary Fig. 10a and Supplementary Fig. 10b ). The distinct subpopulations were FACS sorted and analyzed by RNA-seq. As shown in Figure 6b -e, SMARCD2 is a transcriptional suppressor in immature cells (LSK and CMP cells), while it adopts the role of a transcriptional activator in further differentiated stages (MEP and GMP cells). Among a total of 15,465 detected genes in CMP cells, we found 852 to be differentially expressed at an FDR lower than 10%; the majority (59%) of the 170 genes with a relatively large difference in expression (fold change > 0.8, FDR < 1%) were upregulated and not downregulated (Fig. 6c) . In contrast, among a total of 26,595 detected genes in GMP cells, we found 136 to be differentially expressed at an FDR lower than 10%; the majority (70%) of the 56 genes with a relatively large difference in expression (fold change > 1.5, FDR < 1%) were downregulated and not upregulated (Fig. 6d) . A similar pattern was observed in MEP cells. Among a total of 13,049 detected genes in MEP cells, we found 150 to be differentially expressed at an FDR lower than 10%; again, the majority (84%) of the 37 genes with a relatively large difference in expression (fold change > 1.5, FDR < 1%) were downregulated and not upregulated ( 
SMARCD2 regulates human granule gene expression
The mouse experiments described in the previous subsection suggest that SMARCD2 orchestrates transcriptional networks in early HSCs, but they do not directly explain the striking absence of neutrophil granules and perturbed differentiation of mature neutrophils seen in SMARCD2-deficient human individuals. To shed light on the mechanisms of SMARCD2 in late human neutrophil maturation, we set out to establish a human in vitro system to further study the function of SMARCD2. We chose the promyelocytic cell line NB4 that is responsive to retinoic acid signaling and can be differentiated toward mature neutrophil granulocytes in vitro. Because our attempts to generate SMARCD2-deficient NB4 cells using CRISPR/Cas9 tools were unsuccessful, we decided to make use of RNA interference to establish cell lines characterized by lower SMARCD2 protein expression. We designed lentiviral short hairpin RNA (shRNA) constructs expressing a SMARCD2-specific shRNA and the marker gene GFP, and we transduced and flow sorted NB4 cells for further analysis NB4 cells represent a human promyelocytic leukemia cell line, derived from a patient with a T15/17 translocation.
NB4 cells express SMARCD1, SMARCD2, SMARCD3, and CEBPE mRNA/cDNA at detectable levels ( Fig. 7a and ref. 22 ). RNA expression of SMARCD2, but not of the family members SMARCD1 and SMARCD3, was significantly reduced upon lentiviral expression of shRNA directed against SMARCD2 (Fig. 7a) . The expression of CEBPE was not affected by SMARCD2 knockdown and increased after differentiation with alltrans retinoic acid (ATRA) (data not shown), as previously described (for example, see ref. 23 ). Next, we systematically analyzed the RNA expression of genes encoding proteins that are expressed and stored in primary and specific granules in neutrophil granulocytes (Fig. 7a) . Interestingly, during differentiation with ATRA, transcript levels of the primary granule proteins cathelicidin (CAMP) and α1-antitrypsin (AAT), also known as SERPIN A1, as well as the specific granule proteins matrix metalloproteinase 8 (MMP8), transcobalamin 1 (TCN1), and lactoferrin (LTF), were reduced in SMARCD2-deficient cells. A r t i c l e s
SMARCD2 mediates transcription via CEBPε
Mice with targeted mutations in Cebpe 24 and human patients with rare mutations in CEBPE 25 are characterized by specific granule deficiency and susceptibility to bacterial infections. In view of these phenotypic similarities, we asked whether SMARCD2 controls the effects of CEBPε. RNA expression of CEBPE was not directly affected in SMARCD2-deficient cells. As an alternative, we hypothesized that SMARCD2 might be relevant for recruiting CEBPε to transcription start sites or open chromatin and thus facilitating expression of CEBPε-dependent genes.
CEBPε binds to the promoters of primary granule genes of CAMP and SERPINA1 (AAT) as well as to the promoters of specific granule genes LTF (lactoferrin) and MMP8 (matrix metalloproteinase 8/neutrophil A r t i c l e s collagenase) ( Fig. 7b and Supplementary Fig. 11a-c) . shRNA-mediated knockdown of SMARCD2 significantly impaired binding of CEBPε (CTRL versus shRNA 1, P = 0.004; CTRL versus shRNA 2, P = 0.011, two-tailed unpaired t tests) and BRG1 (CTRL versus shRNA 1, P = 0.036; CTRL versus shRNA 2, P = 0.031, two-tailed unpaired t tests) to the LTF promoter (Fig. 7b) .
To address the question of whether SMARCD2 interacts directly with CEBPε, we performed immunoprecipitation studies in 293T cells engineered to express HA-tagged CEBPε and FLAG-tagged SMARCD2. As shown in Figure 8a,b (Supplementary Data 5) , immunoprecipitation studies confirmed a physical interaction between both proteins. The interaction of the endogenous proteins was demonstrated by immunoprecipitation with antibody to CEBPε and co-precipitation of SMARCD2 (Supplementary Fig. 12a-j) .
A functional link between SMARCD2 and CEBPε is further supported by our finding, that documented CEPBε-dependent genes are deregulated in the absence of SMARCD2 in human (Fig. 8c,  Supplementary Fig. 13 , and Supplementary Table 6d) and mouse ( Fig. 6f and Supplementary Fig. 9b,c) hematopoietic cells. The proportion of CEBPε-dependent genes affected by Smarcd2 −/− was highest in the CMP compartment than in LSK, GMP, or MEP cells (Fig. 6f) . This is in keeping with an established role for CEBPε in intermediate stages of differentiation 26 .
SMARCD2 modulates chromatin accessibility
The consequences of defective nucleosome positioning due to dysfunctional SWI/SNF molecules may be complex. We attempted to interrogate the effects of SMARCD2 deficiency on global chromatin accessibility using the assay for transposase accessible chromatin with high-throughput sequencing (ATAC-seq) (Fig. 8d-g,  Supplementary Fig. 14, and Supplementary Tables 15 and 16) . We compared all genes that showed differential chromatin accessibility in SMARCD2-knockdown cells (Supplementary Fig. 14) with differentially expressed genes determined by RNA-seq studies both in undifferentiated (Fig. 8d,e) and ATRA-differentiated (Fig. 8f,g ) promyelocytic leukemia cell line NB4. A specific subset of genes was found to be deregulated in both assays, ATAC-seq and RNA-seq. These genes are involved in vesicular trafficking, migration, and signaling. The specificity of this observation is in line with findings in mouse embryonal fibroblasts 11 and yeast 27 , which show only a moderate correlation of SWI/SNF-governed chromatin accessibility and transcription in response to knockout of single SWI/SNF units. To examine the role of the discovered gene sets, further studies are needed. Differentially expressed genes in both the mouse transcriptome (Supplementary Tables 4 and 7-10 ) and the human transcriptome (Supplementary Tables 15 and 16 ) clustered significantly in signaling pathways relevant to immune system functions ( Supplementary Fig. 9a and Supplementary Table 6a (mouse); Supplementary Fig. 13a,b and Supplementary Table 6e,f (human)). Taken together, DNA accessibility studies, transcriptome studies, and protein-protein interaction studies suggest that SMARCD2 has a direct role to remodel the chromatin and to mediate downstream effects partly by interaction with the myeloid transcription factor CEBPε.
DISCUSSION
In this study, we identify patients with SMARCD2 deficiency, characterized by hematopoietic defects and developmental aberrations. On the basis of our comparative studies, also involving zebrafish and mice, we conclude that SMARCD2 orchestrates HSC differentiation.
Clinically, the phenotype of SMARCD2-deficient neutrophil granulocytes is reminiscent of the phenotype of specific granule deficiency caused by mutations in CEBPE 28 . CEBPE-deficient neutrophil granulocytes show bilobed nuclei 29, 30 with nuclear blebs and pockets 31 or pseudo-Pelger-Huët-type bilobed nuclei 32 in conjunction with a lack of specific granules 30 .
Both SMARCD2 deficiency and CEBPε deficiency may be associated with decreased counts of peripheral neutrophil granulocytes, yet the capacity to mobilize neutrophils from the bone marrow remains intact.
All patients with SMARCD2 deficiency had evidence of myelodysplasia and blast excess, a feature not typically seen in CEBPε deficiency. However, allelic loss of CEBPE has been detected in 4 of 20 cases of evolving myelodysplastic syndromes (MDS) 33 , and myelodysplasia is also a feature in Cebpe −/− mice 34, 35 . CEPBε controls terminal differentiation of neutrophil granulocytes, whereas SMARCD2 appears to also control early stages of HSC differentiation, as documented by imbalances in the transcriptome in hematopoietic progenitor cells. Even though the effects of SMARCD2 deficiency on late neutrophil granulocytes are mediated, at least in part, by CEBPε, there are other less well-defined modes of action of SMARCD2. 
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The role of the SWI/SNF complex and SMARCD2 in leukemogenesis is intriguing. Previous studies had shown that the SWI/SNF complex controls maintenance of myeloid leukemia cells 13, 36 . Specifically, knockdown of SMARCD2 in human MLL-rearranged leukemia cells resulted in reduced self-renewal capacity 37 . Furthermore, mutational analysis of acute promyelocyte leukemia samples identified somatic loss-of-function mutations in ARID1B and ARID1A, encoding two components of the SWI/SNF complex 38 .
The companion paper by Priam et al. 39 documents a specific and non-redundant role for mouse SMARCD2 in controlling granulocytopoiesis. Similar to our patients with SMARCD2 deficiency, adult mice with SMARCD2-deficient hematopoietic cells develop myelodysplasia and blast excess. It remains to be determined whether this proliferative disorder is indeed clonal.
Interestingly, our transcriptome studies in defined subpopulations of hematopoietic progenitor cells showed an evolving pattern, consistent with the concept that SMARCD2 acts as a transcriptional suppressor in early HSCs and as a transcriptional activator in later stages. We interrogated the genomic landscape in SMARCD2-deficient leukemia cells but could only identify a relatively small number of overlapping genes in ATAC-seq and corresponding RNA transcripts. This may be due to intrinsic limitations of the model system.
The complexity of SMARCD2-dependent transcriptional regulation in early and late hematopoiesis prohibits a simple mechanistic explanation of the leukemogenic disposition. Our studies in human cells and studies in mouse cells 39 documented that SMARCD2 is essential for CEBPε and SWI/SNF recruitment to the promoter of neutrophilic granule genes. Further studies are however needed to shed light on the critical role of SMARCD2 in early stages of HSC differentiation.
Systematic studies in patients with rare disorders may highlight the critical role of defined genes and pathways controlling differentiation and function of the blood and immune system. Our clinical and molecular studies in SMARCD2-deficient patients provide an example and reveal SMARCD2 as a key factor controlling transcriptional networks governing stem cell differentiation and lineage specification in the hematopoietic system. Table 20 Homozygosity mapping and next-generation sequencing. Patient AII.1 served as the index case. Patient BII.1, previously described in a clinical case report 40 , and patient BII.2 (not previously described) were analyzed by homozygosity mapping using the Affymetrix 6.0 chip, as in ref. 41 . We searched for perfectly segregating intervals in the SNP data using the software findhomoz 42 . To compute LOD scores, we assumed that the parents of the affected individuals were second cousins as in refs. 43,44 because they are known not to be first cousins and, if they are more distantly related than second cousins, the LOD scores would be higher. Indeed, in the initial case report, family B was erroneously described as "non-consanguineous" (ref. 40) . Genomic DNA from the two parents and two affected children in family B was enriched for all coding exons using Agilent's SureSelect Human AllExon kit V3-50MB (Agilent Technologies) according to the manufacturer's protocol and subjected to sequencing on an Illumina Genome Analyzer II. Short sequence reads were mapped to human reference genome GRCh37 with Novoalign, and variants were detected as previously described [45] [46] [47] . For each possible mutation found in family B, we designed a sequencing assay to test the affected individual in family A (our index patient) for that mutation. As this approach failed, we performed high-throughput sequencing in family A and identified a likely pathological variant in SMARCD2: c.1181+1G>A (ENST00000448276; NM_001098426.1) confirmed by Sanger sequencing. Sanger sequencing of SMARCD2 in family B identified a large homozygous insertion in patients BII.1 and BII.2 (c.414_438dup), segregating in family B.
Within our cohort of approximately 250 families including a total of 400 patients with SCN, in patient CII.1, a homozygous mutation in SMARCD2 (c.401+2T>C) was identified by whole-exome sequencing with a SureSelect XT Human All-Exon V3 + UTRs kit according to the manufacturer's instructions (Agilent Technologies) using a SOLiD 5500 next-generation sequencing platform (Life Technologies) to obtain an average coverage depth of 100× (75-bp forward and 35-bp reverse paired-end reads). Segregation of this variant in family C was confirmed by Sanger sequencing. In all three families (A, B, and C), CEBPE and several other candidate genes were excluded (shown not to contain germline biallelic mutations) by Sanger sequencing or whole-exome sequencing (ref. 40 and new data, data not shown). The Exome Aggregation Consortium (EXAC) 48 describes seven loss-of-function variants, each occurring once in the heterozygous state among a cohort of 60,000 individuals. This suggests a frequency for homozygous SMARCD2 loss of function in the general population in the range of 1 in 14,400,000,000 to approximately 1 in 2,000,000,000. If multiple loss-of-function variants occur within the same subpopulation, the probability of compound-heterozygous individuals would be higher. See the Supplementary Note for statistics.
Sanger sequencing of SMARCD2. Human SMARCD2 isoform SMARCD2-001 (ENST00000448276; NM_001098426.1) is consistently annotated (CCDS45756) and was used as the reference sequence for specific sequence-based experiments. Targeted sequencing included all 13 exons of ENST00000448276; NM_001098426.1, as well as one potential alternative exon 1 derived from isoform SMARCD2-003 (ENST00000323347; no RefSeq ID). Throughout the text, mutations are described by their putative effect on transcript SMARCD2-001 only. Effects on other transcripts are shown in Supplementary Table 2 . See also the Supplementary Note.
Mouse model. Generation of the Smarcd2-deficient mouse model. C57BL/6 ES cell clone 11930A-F4 carrying a mutant Smarcd2 allele was generated by Regeneron Pharmaceuticals and obtained from the KOMP repository (see URLs). To generate Smarcd2-deficient mice, clonal ES cells were injected into C57BL/6BrdCrHsd-Tyrc (albino) blastocysts and these were transferred to pseudo-pregnant NMRI foster mothers. The resulting chimeras were crossed to C57BL/6 albino mice to identify germline transmission of the targeted allele and to produce mice heterozygous for the mutation. F 1 intercrosses of heterozygous mice resulted in Smarcd2 +/+ , Smarcd2 +/− , and Smarcd2 −/− embryos, which were genotyped using standard PCR reaction conditions ( Supplementary Fig. 7 and Supplementary Table 3) .
Animals were maintained under specific-pathogen-free conditions at 23 °C, 65% humidity with a 12-h light/12-h dark cycle and had free access to a standard rodent diet (V1534, Ssniff) and water. All animal experiments were carried out in accordance with the German Animal Welfare Act with permission from the responsible veterinary authority. Mouse fetal blood cytology. Fetal blood was recovered from sacrificed embryos and washed in HBSS with 3% FCS. Cytological assessment of equal numbers of nucleated cells was performed by cytospins (Shandon Cytofunnel Thermo) and May-Grünwald-Giemsa staining. Blood cells were morphologically assessed using an inverted microscope (Axiovert-II, Zeiss) and photographed. 51 . The web tool CHOPCHOP 51 was used to design gene-specific spacer sequences to contribute to two single-guide RNAs (sgRNAs) for smarcd2 targeting (named S1 and S2 in Supplementary Table 3 ). All CHOPCHOP results were checked against the zebrafish genome database using the Ensembl genome browser. DNA templates for sgRNA synthesis were generated by annealing of two single-stranded DNA oligonucleotides (Sigma-Aldrich) followed by T4 DNA polymerase (New England BioLabs) fill-in, to make a full double-stranded DNA oligonucleotide. For each sgRNA DNA template, one oligonucleotide provided the site-specific sequence (incorporating either S1 or S2) and the second 'constant' oligonucleotide supplied the binding site for the Cas9 enzyme. The sgRNAs were generated by in vitro transcription (mMESSAGE mMA-CHINE SP6 or T7 Transcription Kit, Thermo Fisher Scientific). Transcribed sgRNA was cleaned (Sephadex G-50 spin columns, Roche Diagnostics), and its integrity was checked on 1% agarose TBE gels (Bioline, BIO-41025). See the Supplementary Note for details on statistics.
sgRNA microinjection. Individual sgRNAs (50-200 ng/µl) mixed with 20 µM Cas9 nuclease (New England BioLabs) at a 1:1 ratio were microinjected (500-1,000 pg) into the cytoplasm of one-cell-stage Tg(mpx:EGFP) embryos.
Genotyping of zebrafish. smard2 locus genotyping was performed by DNA sequencing. DNA samples were extracted from single embryos or fin clips of adult fish using the HotSHOT protocol 52 and amplified by PCR (for primers and PCR conditions, see Supplementary Table 3) . Following gel electrophoresis, excised bands (AccuPrep Gel Purification Kit, BIONEER) were sequenced in the Micromon sequencing facility (Monash University) using an Applied Biosystems 3730s Genetic Analyzer. F 0 genotyping documented sgRNA activity. F 1 genotyping was used to identify founders carrying mutated alleles. Mouse LSK transcriptome: RNA-seq. Mouse cell populations were sorted into RLT lysis buffer or buffer composed of 0.2% Triton X-100 (Sigma) and 2 U/µl of RNase Inhibitor (Promega). ERCC spike-in controls (Life Technologies) were added to the cell lysis mix at a 1:1,000 dilution. RNA was cleaned from the crude lysate with Agencourt RNAclean XP SPRI beads (Beckman Coulter). cDNA was synthesized and pre-amplified from 5 µl of lysate as described elsewhere 54 , and 0.7 ng of pre-amplified cDNA was used as input for tagmentation with the Nextera XT Sample Preparation kit (Illumina), where a second amplification round was performed for 12 cycles. For each sample, 5 ng of the final library was pooled, and 10 pmol of the library pool was sequenced with 1 × 50 base sequencing on an Illumina HiSeq 1500.
Statistics: RNA-seq data analysis. We aimed for a sample size of n = 5 according to recommendations for power in RNA-seq 55 , which was reached in LSK samples. For CMP, GMP, and MEP samples, a minimum sample size of n = 3 was accepted. All sorted mouse samples were processed if at least two genotypes per litter were available. The mouse fetal liver samples/cell lysates were randomized for RNA-seq library preparation by assigning a random sample number. During analysis, samples had to be unblinded. Sequencing reads were demultiplexed from the Nextera (i5 and i7) indices. Demultiplexed reads were aligned to the mouse genome (mm10) and ERCC reference using NextGenMap 56 . Count data were generated from mapped reads using featureCounts 57 on Ensembl gene models (GRCm38.74). To remove noise from genes with low expression levels, count data sets were subjected to data-driven gene filtering using the HTSFilter R package 58 .
Differential expression analysis was performed in the DESeq2 R package 59 . For each cell type, the full set of detected genes, their estimated log 2 -transformed fold change in expression, and the adjusted P values (P adj ) from the Wald test are given in Supplementary Tables 4 and 7-10. For Figure 6b -e, we used the 50 genes showing the largest difference (based on P values) between the two groups and applied hierarchical clustering gene-wise and sample-wise with complete linkage based on Euclidian distances of variance-stabilized counts for differentially expressed genes. We display the 2D hierarchical cluster results as a heat map. The reference expression value is the expression average for wildtype cells. To test enrichment of functional categories, we used upregulated (log 2 (fold change) > 0.5) and downregulated (log 2 (fold change) < −0.5) genes as the input list and all detected genes as the background list for gene set enrichment analysis using TopGO. Results obtained using the 'elim' algorithm are shown with the Fisher score in Supplementary Table 5 . Of note, LSK sets were analyzed twice; test results and GO terms are given for both experiments in Supplementary Tables 4 and 5 (first experiment) and Supplementary Tables 7 and 13 (second experiment). Because of low sample size in the second experiment, only the heat map for the first experiment is shown (Fig. 6b) .
Expression of neutrophil-specific granule genes in NB4 cells. NB4 AML cells were transduced with specific shRNAs against SMARCD2 (clone 1, V3LHS_ 300463; clone 2, V3LHS_400374) or non-silencing control (RHS4531) and grown in complete RPMI medium with 1 µM ATRA (dissolved in DMSO). The medium was replaced with RPMI medium supplemented with ATRA after 3 d. Cells were analyzed on days 3 and 6. RNA was extracted, cDNA was transcribed, and the expression levels of SMARCD1, SMARCD2, and SMARCD3 as well as granule genes LTF, MMP8, TCN1, CAMP, and AAT (SERPIN A1) normalized to GAPDH were detected by SYBR Green-based qPCR on an ABI
Step One plus cycler. NB4 cells (obtained from DSMZ-German Collection of Microorganisms and Cell Cultures) have been regularly tested for mycoplasma (according to laboratory routine) and were found negative. 
Chromatin immunoprecipitation.
ChIP was performed as previously described [60] [61] [62] [63] . Details are provided in the Supplementary Note. RNA-seq in differentiated NB4 AML cells. NB4 AML cells transduced with specific shRNAs against SMARCD2 (clone 1, V3LHS_300463; clone 2, V3LHS_400374) or non-silencing control (RHS4531) were grown in complete RPMI medium containing 1 µM ATRA (dissolved in DMSO) or DMSO only (control) for 3 d. RNA was extracted from 1 million NB4 cells (shRNAtreated and control cells) with or without ATRA-induced differentiation. RNA was extracted using the GeneJET RNA Purification kit (Thermo Fisher Scientific), and RNA-seq library preparation was performed with the NEBNext Ultra RNA Library Prep Kit for Illumina (E7530 S, New England BioLabs) according to the manufacturer's instructions and sequenced on an Illumina NextSeq 500 instrument at the Dr. von Hauner Children's Hospital NGS facility. The six libraries were sequenced together using a Mid output cartridge (FC-404-2001, 150 cycles, paired-end sequencing) reaching approximately 2 × 5 Gb per sample.
ATAC-seq in differentiated NB4 AML cells. ATAC-seq was performed as described previously 64 . NB4 cells (ACC207) were cultured as described above. DMSO (Sigma-Aldrich) was used as a carrier for ATRA. Cells were kept in logarithmic growth and stimulated with 1 µM ATRA or DMSO as a control. After 72 h, 50,000 cells per condition were collected and nucleus preparation was performed as described 64 . Isolated nuclei were treated with Tn5 transposase from the Nextera DNA Library Preparation kit (Illumina, FC-140-1089) for 30 min at 300 r.p.m. in a Thermomixer. Transposed DNA was purified with the Qiagen MinElute Reaction Cleanup kit (Qiagen, 28204) and amplified with Illumina Tn5-compatible barcoding primers (Supplementary Table 3; 
